Scholarlink

<p>Mutations in <i>LRRK2</i>, a leading genetic cause of Parkinson’s disease (PD), are linked to immune dysregulation, but the immune profiles in the periphery and central nervous system (CNS) remain incompletely defined. This study utilized a large cohort of serum samples (<i>n</i> = 651) and matched CSF samples (<i>n</i> = 129) from <i>LRRK2</i> mutation carriers and non-carriers, with and without PD, to assess immune regulators using Luminex immunoassay. After correction for multiple comparisons, <i>LRRK2</i> mutations were associated with significantly elevated serum levels of SDF-1 alpha and TNF-RII, while CSF markers such as BAFF, CD40L, and IL-27 were nominally reduced. Regardless of <i>LRRK2</i> status, PD was associated with nominally lower levels of inflammatory analytes in CSF, with minimal changes observed in serum. Correlation analyses revealed distinct immune profiles between serum and CSF, suggesting compartmentalized immune responses. These findings highlight immune alterations in <i>LRRK2</i> mutation carriers and PD, providing potential serum markers for monitoring immune responses and avenues for mechanistic studies.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Soluble immune factor profiles in blood and CSF associated with LRRK2 mutations and Parkinson’s disease

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年11月27日

查看全文
  • Roshni Jaffery,
  • Yuhang Zhao,
  • Sarfraz Ahmed,
  • Jackson G. Schumacher,
  • Jae Ahn,
  • Leilei Shi,
  • Yujia Wang,
  • Yukun Tan,
  • Jiayin Zhang,
  • Ken Chen,
  • Hussein Tawbi,
  • Jian Wang,
  • Michael A. Schwarzschild,
  • Weiyi Peng,
  • Xiqun Chen

摘要

Mutations in LRRK2, a leading genetic cause of Parkinson’s disease (PD), are linked to immune dysregulation, but the immune profiles in the periphery and central nervous system (CNS) remain incompletely defined. This study utilized a large cohort of serum samples (n = 651) and matched CSF samples (n = 129) from LRRK2 mutation carriers and non-carriers, with and without PD, to assess immune regulators using Luminex immunoassay. After correction for multiple comparisons, LRRK2 mutations were associated with significantly elevated serum levels of SDF-1 alpha and TNF-RII, while CSF markers such as BAFF, CD40L, and IL-27 were nominally reduced. Regardless of LRRK2 status, PD was associated with nominally lower levels of inflammatory analytes in CSF, with minimal changes observed in serum. Correlation analyses revealed distinct immune profiles between serum and CSF, suggesting compartmentalized immune responses. These findings highlight immune alterations in LRRK2 mutation carriers and PD, providing potential serum markers for monitoring immune responses and avenues for mechanistic studies.